| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.538 | 0.015 | 0.544 | Nootropic | 0.544 0.015 DBMET03563 0.205 0.151 DBMET03565 | DBMET03563 | |
| 0.456 | 0.003 | 0.456 | H+/K+-transporting ATPase inhibitor | 0.319 0.004 DBMET03563 | ||
| 0.433 | 0.004 | 0.433 | Gastric antisecretory | 0.239 0.007 DBMET03563 0.105 0.06 DBMET03565 | ||
| 0.466 | 0.045 | 0.649 | Antiobesity | 0.649 0.015 DBMET03563 0.265 0.143 DBMET03565 | DBMET03563 | |
| 0.395 | 0.012 | 0.395 | 5 Hydroxytryptamine antagonist | |||
| 0.385 | 0.004 | 0.385 | TRPA1 antagonist | 0.19 0.005 DBMET03563 0.061 0.042 DBMET03565 | ||
| 0.31 | 0.024 | 0.31 | 5 Hydroxytryptamine 1E antagonist | 0.182 0.151 DBMET03563 0.203 0.128 DBMET03565 | ||
| 0.294 | 0.015 | 0.294 | Antipruritic | 0.247 0.025 DBMET03563 0.134 0.116 DBMET03565 | ||
| 0.267 | 0.01 | 0.267 | 5 Hydroxytryptamine 3E antagonist | 0.193 0.076 DBMET03563 0.213 0.044 DBMET03565 | ||
| 0.25 | 0.003 | 0.25 | 5 Hydroxytryptamine 6 antagonist | 0.076 0.025 DBMET03563 | ||
| 0.24 | 0.004 | 0.24 | 5 Hydroxytryptamine 5 antagonist | 0.055 0.045 DBMET03565 | ||
| 0.228 | 0.004 | 0.228 | 5 Hydroxytryptamine 5A antagonist | 0.062 0.041 DBMET03565 | ||
| 0.173 | 0.022 | 0.173 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.171 | 0.026 | 0.171 | Calcium channel N-type blocker | 0.1 0.096 DBMET03563 | ||
| 0.185 | 0.045 | 0.33 | Hexokinase inhibitor | 0.33 0.008 DBMET03563 0.171 0.057 DBMET03565 | DBMET03563 | |
| 0.163 | 0.025 | 0.163 | Ca(v)2.2 blocker | |||
| 0.15 | 0.016 | 0.15 | 5 Hydroxytryptamine 1F antagonist | |||
| 0.158 | 0.041 | 0.158 | 5 Hydroxytryptamine 2 antagonist | |||
| 0.117 | 0.005 | 0.117 | Secretase gamma inhibitor | 0.112 0.005 DBMET03563 | ||
| 0.133 | 0.033 | 0.133 | 5 Hydroxytryptamine 2A antagonist | |||
| 0.218 | 0.119 | 0.218 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.199 0.168 DBMET03565 | ||
| 0.102 | 0.005 | 0.102 | Kallikrein 7 inhibitor | 0.099 0.005 DBMET03563 | ||
| 0.145 | 0.063 | 0.158 | Pregnane X receptor agonist | 0.158 0.04 DBMET03563 | DBMET03563 | |
| 0.134 | 0.054 | 0.134 | Papain-like protease (SARS coronavirus) inhibitor | |||
| 0.18 | 0.1 | 0.277 | Histone acetyltransferase inhibitor | 0.215 0.049 DBMET03563 0.277 0.018 DBMET03565 | DBMET03565 | |
| 0.098 | 0.026 | 0.098 | Transforming growth factor beta 3 antagonist | 0.089 0.041 DBMET03565 | ||
| 0.096 | 0.027 | 0.096 | Cannabinoid receptor agonist | |||
| 0.158 | 0.093 | 0.212 | Amyloid beta precursor protein antagonist | 0.212 0.05 DBMET03563 | DBMET03563 | |
| 0.07 | 0.011 | 0.121 | Carnitine palmitoyltransferase 1B inhibitor | 0.121 0.004 DBMET03563 0.05 0.029 DBMET03565 | DBMET03563 | |
| 0.076 | 0.027 | 0.076 | Cannabinoid CB2 receptor agonist | |||
| 0.048 | 0.005 | 0.048 | 5 Hydroxytryptamine 6 agonist | 0.034 0.012 DBMET03563 | ||
| 0.16 | 0.12 | 0.16 | Growth factor agonist | 0.156 0.128 DBMET03565 | ||
| 0.053 | 0.012 | 0.053 | Nicotinamide phosphoribosyltransferase inhibitor | |||
| 0.12 | 0.081 | 0.124 | Antibacterial (Helicobacter pylori) | 0.124 0.076 DBMET03565 | DBMET03565 | |
| 0.065 | 0.028 | 0.075 | Bombesin 3 receptor antagonist | 0.075 0.021 DBMET03563 | DBMET03563 | |
| 0.067 | 0.034 | 0.067 | Collagenase 3 inhibitor | 0.059 0.042 DBMET03563 | ||
| 0.067 | 0.04 | 0.067 | 5 Hydroxytryptamine 7 antagonist | |||
| 0.061 | 0.04 | 0.077 | Potassium channel intermediate-conductance Ca-activated blocker | 0.077 0.019 DBMET03563 | DBMET03563 | |
| 0.186 | 0.168 | 0.186 | MAP kinase kinase 3 inhibitor | |||
| 0.04 | 0.025 | 0.04 | VCAM-1 antagonist | 0.04 0.025 DBMET03563 | ||
| 0.04 | 0.025 | 0.04 | VCAM antagonist | 0.04 0.025 DBMET03563 | ||
| 0.065 | 0.051 | 0.065 | 5 Hydroxytryptamine agonist | |||
| 0.029 | 0.015 | 0.029 | Myristoyl transferase inhibitor | |||
| 0.117 | 0.105 | 0.253 | Mannose-6-phosphate isomerase inhibitor | 0.253 0.011 DBMET03563 0.223 0.02 DBMET03565 | DBMET03563 | |
| 0.098 | 0.087 | 0.098 | Calcium channel (voltage-sensitive) blocker | |||
| 0.057 | 0.048 | 0.057 | Adrenaline uptake inhibitor | |||
| 0.108 | 0.1 | 0.108 | Sodium channel blocker | |||
| 0.032 | 0.024 | 0.032 | Vanilloid 4 antagonist | |||
| 0.055 | 0.047 | 0.055 | Cannabinoid CB1 receptor agonist | |||
| 0.032 | 0.025 | 0.032 | ATR kinase inhibitor | |||
| 0.028 | 0.021 | 0.028 | CDK4/cyclin D3 inhibitor | |||
| 0.019 | 0.014 | 0.019 | Follicle-stimulating hormone antagonist | |||
| 0.061 | 0.057 | 0.061 | Nav1.7 sodium channel blocker | |||
| 0.102 | 0.103 | 0.17 | Cyclooxygenase 2 inhibitor | 0.17 0.042 DBMET03563 | DBMET03563 | |
| 0.128 | 0.13 | 0.142 | Tumour necrosis factor antagonist | 0.142 0.111 DBMET03563 0.136 0.119 DBMET03565 | DBMET03563 | |
| 0.024 | 0.029 | 0.046 | Carnitine palmitoyltransferase 1A inhibitor | 0.046 0.008 DBMET03563 | DBMET03563 | |
| 0.097 | 0.102 | 0.109 | Nav1.3 sodium channel blocker | 0.109 0.087 DBMET03565 | DBMET03565 | |
| 0.01 | 0.019 | 0.019 | 5 Lipoxygenase activating protein inhibitor | 0.016 0.007 DBMET03563 0.019 0.005 DBMET03565 | DBMET03565 | |
| 0.084 | 0.095 | 0.109 | Phosphodiesterase 6D inhibitor | 0.109 0.037 DBMET03563 0.1 0.053 DBMET03565 | DBMET03563 | |
| 0.095 | 0.107 | 0.128 | MAP kinase 12 inhibitor | 0.128 0.061 DBMET03565 | DBMET03565 | |
| 0.02 | 0.034 | 0.025 | Glutamate (mGluR1) agonist | 0.023 0.021 DBMET03563 0.025 0.016 DBMET03565 | DBMET03565 | |
| 0.064 | 0.079 | 0.072 | Phosphodiesterase VI inhibitor | 0.072 0.056 DBMET03563 | DBMET03563 | |
| 0.117 | 0.135 | 0.143 | CC chemokine 6 receptor antagonist | 0.143 0.034 DBMET03563 0.122 0.109 DBMET03565 | DBMET03563 | |
| 0.013 | 0.032 | 0.02 | CC chemokine 9 receptor antagonist | 0.02 0.007 DBMET03563 | DBMET03563 | |
| 0.013 | 0.034 | 0.035 | Hexokinase stimulant | 0.035 0.007 DBMET03563 | DBMET03563 | |
| 0.025 | 0.056 | 0.037 | Alpha 1d adrenoreceptor agonist | 0.037 0.029 DBMET03565 | DBMET03565 | |
| 0.081 | 0.115 | 0.123 | MAP kinase 13 inhibitor | 0.123 0.054 DBMET03565 | DBMET03565 | |
| 0.011 | 0.049 | 0.018 | Bombesin 3 receptor agonist | 0.018 0.016 DBMET03563 0.018 0.015 DBMET03565 | DBMET03565 | |
| 0.023 | 0.061 | 0.138 | RNA-directed RNA polymerase inhibitor | 0.074 0.007 DBMET03563 0.138 0.004 DBMET03565 | DBMET03565 | |
| 0.017 | 0.056 | 0.116 | HCV NS5B polymerase inhibitor | 0.066 0.008 DBMET03563 0.116 0.004 DBMET03565 | DBMET03565 | |
| 0.018 | 0.057 | 0.027 | Integrin alpha2beta1 antagonist | 0.027 0.016 DBMET03565 | DBMET03565 | |
| 0.086 | 0.127 | 0.1 | Cell adhesion inhibitor | 0.1 0.089 DBMET03563 | DBMET03563 | |
| 0.013 | 0.055 | 0.022 | Bombesin agonist | 0.021 0.018 DBMET03563 0.022 0.016 DBMET03565 | DBMET03565 | |
| 0.028 | 0.072 | 0.042 | Thymidylate synthase inhibitor | 0.042 0.039 DBMET03565 | DBMET03565 | |
| 0.008 | 0.055 | 0.022 | Prostaglandin D2 antagonist | 0.022 0.017 DBMET03563 | DBMET03563 | |
| 0.092 | 0.139 | 0.171 | Cyclooxygenase inhibitor | 0.171 0.056 DBMET03563 | DBMET03563 | |
| 0.011 | 0.061 | 0.032 | Glutamate (mGluR1a) agonist | 0.032 0.008 DBMET03563 0.026 0.011 DBMET03565 | DBMET03563 | |
| 0.049 | 0.103 | 0.068 | Transforming growth factor antagonist | 0.068 0.051 DBMET03565 | DBMET03565 | |
| 0.021 | 0.075 | 0.034 | Peroxisome proliferator-activated receptor delta antagonist | 0.034 0.022 DBMET03563 | DBMET03563 | |
| 0.013 | 0.067 | 0.027 | Liver X receptor beta antagonist | 0.027 0.022 DBMET03563 | DBMET03563 | |
| 0.169 | 0.227 | 0.381 | 5 Hydroxytryptamine uptake stimulant | 0.261 0.07 DBMET03563 0.381 0.018 DBMET03565 | DBMET03565 | |
| 0.039 | 0.1 | 0.076 | MAP kinase 14 inhibitor | 0.076 0.05 DBMET03565 | DBMET03565 | |
| 0.075 | 0.136 | 0.128 | Protein kinase (CK1) inhibitor | 0.128 0.084 DBMET03565 | DBMET03565 | |
| 0.056 | 0.119 | 0.072 | Cell adhesion molecule inhibitor | 0.072 0.066 DBMET03563 | DBMET03563 | |
| 0.022 | 0.091 | 0.045 | Integrin alpha2 antagonist | 0.045 0.015 DBMET03565 | DBMET03565 | |
| 0.046 | 0.116 | 0.067 | CYP2A6 inhibitor | 0.067 0.064 DBMET03565 | DBMET03565 | |
| 0.023 | 0.097 | 0.11 | Prostaglandin antagonist | 0.11 0.015 DBMET03563 0.065 0.029 DBMET03565 | DBMET03563 | |
| 0.005 | 0.084 | 0.039 | Prostaglandin H2 antagonist | 0.039 0.006 DBMET03563 | DBMET03563 | |
| 0.052 | 0.142 | 0.19 | GABA A receptor agonist | 0.19 0.011 DBMET03565 | DBMET03565 | |
| 0.142 | 0.239 | 0.235 | Nitric-oxide synthase stimulant | 0.235 0.044 DBMET03565 | DBMET03565 | |
| 0.012 | 0.11 | 0.054 | Kinesin antagonist | 0.054 0.015 DBMET03565 | DBMET03565 | |
| 0.012 | 0.11 | 0.054 | Kinesin-like protein 1 inhibitor | 0.054 0.015 DBMET03565 | DBMET03565 | |
| 0.054 | 0.153 | 0.104 | Protein kinase (CK1) delta inhibitor | 0.104 0.088 DBMET03565 | DBMET03565 | |
| 0.227 | 0.327 | 0.601 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.268 0.258 DBMET03563 0.601 0.007 DBMET03565 | DBMET03565 | |
| 0.021 | 0.121 | 0.036 | Protein kinase C beta I inhibitor | 0.036 0.017 DBMET03565 | DBMET03565 | |
| 0.028 | 0.13 | 0.093 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.057 0.033 DBMET03563 0.093 0.012 DBMET03565 | DBMET03565 | |
| 0.084 | 0.194 | 0.21 | Protein kinase (CK1) gamma 3 inhibitor | 0.21 0.041 DBMET03565 | DBMET03565 | |
| 0.076 | 0.189 | 0.17 | Protein kinase (CK1) gamma 1 inhibitor | 0.17 0.055 DBMET03565 | DBMET03565 | |
| 0.074 | 0.188 | 0.138 | Interleukin 8 antagonist | 0.138 0.043 DBMET03565 | DBMET03565 | |
| 0.069 | 0.188 | 0.165 | NADPH oxidase inhibitor | 0.165 0.046 DBMET03565 | DBMET03565 | |
| 0.011 | 0.135 | 0.185 | TRPM8 blocker | 0.059 0.012 DBMET03563 0.185 0.004 DBMET03565 | DBMET03565 | |
| 0.056 | 0.184 | 0.118 | ABCA1 expression enhancer | 0.118 0.032 DBMET03563 0.114 0.035 DBMET03565 | DBMET03563 | |
| 0.044 | 0.175 | 0.214 | Pim-1 kinase inhibitor | 0.214 0.012 DBMET03565 | DBMET03565 | |
| 0.044 | 0.176 | 0.099 | Potassium channel activator | 0.099 0.049 DBMET03565 | DBMET03565 | |
| 0.01 | 0.15 | 0.046 | Carnitine palmitoyltransferase inhibitor | 0.046 0.011 DBMET03563 0.035 0.022 DBMET03565 | DBMET03563 | |
| 0.055 | 0.198 | 0.19 | MAP kinase kinase inhibitor | 0.19 0.032 DBMET03565 | DBMET03565 | |
| 0.05 | 0.196 | 0.277 | GABA receptor agonist | 0.277 0.008 DBMET03565 | DBMET03565 | |
| 0.01 | 0.157 | 0.045 | Carnitine palmitoyltransferase 1 inhibitor | 0.045 0.01 DBMET03563 0.035 0.023 DBMET03565 | DBMET03563 | |
| 0.017 | 0.17 | 0.039 | DNA topoisomerase IV inhibitor | 0.039 0.009 DBMET03565 | DBMET03565 | |
| 0.025 | 0.183 | 0.091 | Glutamate receptor agonist | 0.091 0.044 DBMET03565 | DBMET03565 | |
| 0.052 | 0.211 | 0.219 | Electrolyte absorption antagonist | 0.167 0.014 DBMET03563 0.219 0.006 DBMET03565 | DBMET03565 | |
| 0.028 | 0.19 | 0.058 | Antiviral (Hepatitis D) | 0.058 0.025 DBMET03565 | DBMET03565 | |
| 0.021 | 0.184 | 0.058 | Protein kinase C eta inhibitor | 0.058 0.035 DBMET03565 | DBMET03565 | |
| 0.055 | 0.22 | 0.174 | Protein kinase (CK1) gamma inhibitor | 0.174 0.055 DBMET03565 | DBMET03565 | |
| 0.052 | 0.218 | 0.128 | Caspase 3 inhibitor | 0.128 0.049 DBMET03563 | DBMET03563 | |
| 0.023 | 0.194 | 0.053 | Carbonic anhydrase stimulant | 0.053 0.05 DBMET03565 | DBMET03565 | |
| 0.049 | 0.22 | 0.115 | Cyclooxygenase 1 inhibitor | 0.115 0.085 DBMET03563 | DBMET03563 | |
| 0.058 | 0.23 | 0.185 | Protein kinase C nu inhibitor | 0.185 0.053 DBMET03565 | DBMET03565 | |
| 0.019 | 0.191 | 0.082 | Pim-2 kinase inhibitor | 0.082 0.02 DBMET03565 | DBMET03565 | |
| 0.088 | 0.26 | 0.271 | 3C-like protease (Human coronavirus) inhibitor | 0.146 0.109 DBMET03563 0.271 0.019 DBMET03565 | DBMET03565 | |
| 0.023 | 0.196 | 0.061 | Dopamine beta hydroxylase inhibitor | 0.061 0.014 DBMET03565 | DBMET03565 | |
| 0.025 | 0.198 | 0.069 | Topoisomerase II beta inhibitor | 0.069 0.017 DBMET03565 | DBMET03565 | |
| 0.024 | 0.199 | 0.039 | CF transmembrane conductance regulator antagonist | 0.039 0.029 DBMET03565 | DBMET03565 | |
| 0.047 | 0.23 | 0.133 | Nav1.6 sodium channel blocker | 0.133 0.077 DBMET03565 | DBMET03565 | |
| 0.049 | 0.24 | 0.144 | Protein kinase (CK1) gamma 2 inhibitor | 0.144 0.051 DBMET03565 | DBMET03565 | |
| 0.076 | 0.274 | 0.19 | Death-associated protein kinase 3 inhibitor | 0.19 0.08 DBMET03565 | DBMET03565 | |
| 0.002 | 0.202 | 0.029 | Thrombopoietin agonist | 0.029 0.003 DBMET03565 | DBMET03565 | |
| 0.083 | 0.283 | 0.156 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.156 0.136 DBMET03565 | DBMET03565 | |
| 0.035 | 0.239 | 0.091 | Protein kinase C delta inhibitor | 0.091 0.061 DBMET03565 | DBMET03565 | |
| 0.043 | 0.253 | 0.251 | AMP-activated protein kinase stimulant | 0.118 0.051 DBMET03563 0.251 0.007 DBMET03565 | DBMET03565 | |
| 0.022 | 0.232 | 0.076 | Nav1.8 sodium channel blocker | 0.076 0.048 DBMET03565 | DBMET03565 | |
| 0.02 | 0.232 | 0.053 | Sphingosine 1-phosphate receptor 3 antagonist | 0.053 0.049 DBMET03565 | DBMET03565 | |
| 0.015 | 0.227 | 0.058 | Mineralocorticoid receptor antagonist | 0.058 0.021 DBMET03565 | DBMET03565 | |
| 0.021 | 0.236 | 0.054 | Aldosterone antagonist | 0.054 0.025 DBMET03565 | DBMET03565 | |
| 0.03 | 0.254 | 0.134 | Pim-3 kinase inhibitor | 0.134 0.024 DBMET03565 | DBMET03565 | |
| 0.019 | 0.244 | 0.182 | Phenylalanine 4-hydroxylase inhibitor | 0.182 0.008 DBMET03565 | DBMET03565 | |
| 0.039 | 0.267 | 0.147 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.147 0.079 DBMET03565 | DBMET03565 | |
| 0.007 | 0.236 | 0.09 | AMPA receptor antagonist | 0.09 0.014 DBMET03565 | DBMET03565 | |
| 0.016 | 0.246 | 0.115 | Benzodiazepine agonist | 0.115 0.018 DBMET03565 | DBMET03565 | |
| 0.026 | 0.257 | 0.071 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.071 0.057 DBMET03565 | DBMET03565 | |
| 0.028 | 0.261 | 0.088 | HIV-1 integrase inhibitor | 0.088 0.033 DBMET03565 | DBMET03565 | |
| 0.053 | 0.29 | 0.102 | Glutamate release inhibitor | 0.102 0.039 DBMET03565 | DBMET03565 | |
| 0.14 | 0.38 | 0.469 | Cyclophilin D inhibitor | 0.469 0.06 DBMET03563 0.429 0.076 DBMET03565 | DBMET03563 | |
| 0.039 | 0.281 | 0.092 | Bile acid receptor antagonist | 0.092 0.067 DBMET03563 0.092 0.069 DBMET03565 | DBMET03565 | |
| 0.014 | 0.257 | 0.047 | Benzodiazepine antagonist | 0.047 0.032 DBMET03565 | DBMET03565 | |
| 0.009 | 0.254 | 0.035 | Protein kinase C beta II inhibitor | 0.035 0.017 DBMET03565 | DBMET03565 | |
| 0.039 | 0.284 | 0.156 | Alkaline phosphatase inhibitor | 0.116 0.091 DBMET03563 0.156 0.056 DBMET03565 | DBMET03565 | |
| 0.065 | 0.314 | 0.499 | NOS3 expression enhancer | 0.235 0.03 DBMET03563 0.499 0.005 DBMET03565 | DBMET03565 | |
| 0.012 | 0.263 | 0.051 | Nerve growth factor antagonist | 0.051 0.017 DBMET03565 | DBMET03565 | |
| 0.05 | 0.304 | 0.19 | LIM domain kinase 1 inhibitor | 0.19 0.068 DBMET03565 | DBMET03565 | |
| 0.023 | 0.279 | 0.089 | MAP-kinase-activated kinase 2 inhibitor | 0.089 0.035 DBMET03565 | DBMET03565 | |
| 0.004 | 0.268 | 0.045 | Kynurenine 3 monooxygenase inhibitor | 0.032 0.014 DBMET03563 0.045 0.008 DBMET03565 | DBMET03565 | |
| 0.009 | 0.274 | 0.032 | Glutamate (mGluR group II) agonist | 0.032 0.027 DBMET03565 | DBMET03565 | |
| 0.027 | 0.292 | 0.159 | Myeloperoxidase inhibitor | 0.159 0.009 DBMET03565 | DBMET03565 | |
| 0.014 | 0.285 | 0.078 | CDC7 inhibitor | 0.078 0.037 DBMET03565 | DBMET03565 | |
| 0.018 | 0.293 | 0.049 | Guanylate cyclase stimulant | 0.049 0.022 DBMET03565 | DBMET03565 | |
| 0.027 | 0.303 | 0.099 | MAP-kinase-activated kinase inhibitor | 0.099 0.04 DBMET03565 | DBMET03565 | |
| 0.004 | 0.281 | 0.059 | Methionyl aminopeptidase 2 inhibitor | 0.059 0.005 DBMET03565 | DBMET03565 | |
| 0.012 | 0.289 | 0.096 | Prostaglandin-E synthase inhibitor | 0.096 0.029 DBMET03565 | DBMET03565 | |
| 0.034 | 0.323 | 0.152 | MAP kinase kinase 1 inhibitor | 0.152 0.016 DBMET03565 | DBMET03565 | |
| 0.015 | 0.307 | 0.04 | Glutamate (mGluR group III) agonist | 0.04 0.034 DBMET03565 | DBMET03565 | |
| 0.087 | 0.386 | 0.515 | 5 Hydroxytryptamine release stimulant | 0.515 0.025 DBMET03565 | DBMET03565 | |
| 0.012 | 0.315 | 0.044 | Protein kinase (CK2) beta inhibitor | 0.044 0.01 DBMET03565 | DBMET03565 | |
| 0.021 | 0.326 | 0.092 | Pregnane X receptor antagonist | 0.056 0.041 DBMET03563 0.092 0.004 DBMET03565 | DBMET03565 | |
| 0.015 | 0.327 | 0.085 | Check point kinase 2 inhibitor | 0.085 0.079 DBMET03565 | DBMET03565 | |
| 0.008 | 0.321 | 0.019 | Somatostatin 3 agonist | 0.019 0.012 DBMET03565 | DBMET03565 | |
| 0.035 | 0.348 | 0.093 | Bromodomain-containing protein 2 inhibitor | 0.093 0.051 DBMET03565 | DBMET03565 | |
| 0.014 | 0.331 | 0.104 | Protein kinase C beta inhibitor | 0.104 0.012 DBMET03565 | DBMET03565 | |
| 0.034 | 0.351 | 0.218 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.218 0.064 DBMET03565 | DBMET03565 | |
| 0.036 | 0.354 | 0.159 | Dyrk kinase inhibitor | 0.159 0.128 DBMET03565 | DBMET03565 | |
| 0.005 | 0.326 | 0.037 | AMPA 3 receptor antagonist | 0.037 0.015 DBMET03565 | DBMET03565 | |
| 0.042 | 0.364 | 0.141 | TRKC antagonist | 0.141 0.109 DBMET03565 | DBMET03565 | |
| 0.053 | 0.377 | 0.188 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.188 0.086 DBMET03565 | DBMET03565 | |
| 0.004 | 0.33 | 0.09 | Somatostatin 5 antagonist | 0.09 0.007 DBMET03565 | DBMET03565 | |
| 0.04 | 0.368 | 0.113 | Carbonic anhydrase XV inhibitor | 0.113 0.052 DBMET03565 | DBMET03565 | |
| 0.03 | 0.364 | 0.156 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.156 0.085 DBMET03565 | DBMET03565 | |
| 0.011 | 0.352 | 0.058 | 5 Hydroxytryptamine 2A agonist | 0.058 0.049 DBMET03565 | DBMET03565 | |
| 0.004 | 0.344 | 0.054 | Free fatty acid receptor 1 antagonist | 0.054 0.007 DBMET03565 | DBMET03565 | |
| 0.072 | 0.414 | 0.173 | MAP kinase kinase 4 inhibitor | 0.173 0.03 DBMET03565 | DBMET03565 | |
| 0.021 | 0.364 | 0.227 | Glycogen synthase kinase-3 alpha inhibitor | 0.227 0.033 DBMET03565 | DBMET03565 | |
| 0.031 | 0.377 | 0.153 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.153 0.128 DBMET03565 | DBMET03565 | |
| 0.033 | 0.381 | 0.116 | Beta amyloid protein antagonist | 0.116 0.071 DBMET03565 | DBMET03565 | |
| 0.018 | 0.372 | 0.248 | Alcohol dehydrogenase inhibitor | 0.248 0.008 DBMET03565 | DBMET03565 | |
| 0.01 | 0.364 | 0.192 | Dihydroorotase inhibitor | 0.042 0.036 DBMET03563 0.192 0.003 DBMET03565 | DBMET03565 | |
| 0.018 | 0.382 | 0.076 | Aryl hydrocarbon receptor antagonist | 0.076 0.031 DBMET03565 | DBMET03565 | |
| 0.017 | 0.386 | 0.065 | Prostaglandin F2 alpha antagonist | 0.059 0.048 DBMET03563 0.065 0.038 DBMET03565 | DBMET03565 | |
| 0.083 | 0.456 | 0.194 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.194 0.165 DBMET03565 | DBMET03565 | |
| 0.017 | 0.393 | 0.059 | Fatty acid synthase inhibitor | 0.059 0.037 DBMET03565 | DBMET03565 | |
| 0.031 | 0.408 | 0.311 | MAP kinase kinase 2 inhibitor | 0.311 0.031 DBMET03565 | DBMET03565 | |
| 0.016 | 0.393 | 0.105 | Protein kinase C zeta inhibitor | 0.105 0.045 DBMET03565 | DBMET03565 | |
| 0.012 | 0.391 | 0.087 | Acetylcholine nicotinic agonist | 0.087 0.048 DBMET03565 | DBMET03565 | |
| 0.048 | 0.428 | 0.137 | Non-steroidal antiinflammatory agent | 0.137 0.136 DBMET03565 | DBMET03565 | |
| 0.004 | 0.387 | 0.039 | Urate transporter 1 inhibitor | 0.038 0.029 DBMET03563 0.039 0.027 DBMET03565 | DBMET03565 | |
| 0.007 | 0.394 | 0.034 | Bombesin 1 receptor antagonist | 0.034 0.03 DBMET03565 | DBMET03565 | |
| 0.078 | 0.466 | 0.308 | Insulysin inhibitor | 0.308 0.054 DBMET03565 | DBMET03565 | |
| 0.014 | 0.402 | 0.061 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.061 0.007 DBMET03565 | DBMET03565 | |
| 0.016 | 0.405 | 0.06 | 5 Hydroxytryptamine 3 agonist | 0.06 0.048 DBMET03565 | DBMET03565 | |
| 0.068 | 0.458 | 0.142 | Death-associated protein kinase 2 inhibitor | 0.142 0.125 DBMET03565 | DBMET03565 | |
| 0.01 | 0.4 | 0.031 | Melatonin receptor 1A agonist | 0.031 0.029 DBMET03565 | DBMET03565 | |
| 0.02 | 0.411 | 0.067 | Peroxisome proliferator-activated receptor gamma antagonist | 0.067 0.06 DBMET03565 | DBMET03565 | |
| 0.011 | 0.407 | 0.174 | Porphobilinogen synthase inhibitor | 0.073 0.053 DBMET03563 0.174 0.016 DBMET03565 | DBMET03565 | |
| 0.034 | 0.437 | 0.175 | Hypolipemic | 0.175 0.114 DBMET03563 | DBMET03563 | |
| 0.032 | 0.435 | 0.106 | MDM2 inhibitor | 0.106 0.005 DBMET03565 | DBMET03565 | |
| 0.021 | 0.425 | 0.181 | Protein kinase C gamma inhibitor | 0.181 0.019 DBMET03565 | DBMET03565 | |
| 0.021 | 0.426 | 0.097 | Somatostatin 1 agonist | 0.097 0.036 DBMET03565 | DBMET03565 | |
| 0.011 | 0.417 | 0.049 | Retinoid X alpha receptor antagonist | 0.032 0.029 DBMET03563 0.049 0.007 DBMET03565 | DBMET03565 | |
| 0.032 | 0.439 | 0.095 | Lanosterol 14 alpha demethylase inhibitor | 0.095 0.064 DBMET03565 | DBMET03565 | |
| 0.007 | 0.418 | 0.041 | Purinergic P2Y14 antagonist | 0.041 0.011 DBMET03565 | DBMET03565 | |
| 0.011 | 0.424 | 0.056 | Retinoid X receptor antagonist | 0.036 0.03 DBMET03563 0.056 0.008 DBMET03565 | DBMET03565 | |
| 0.002 | 0.418 | 0.04 | Nicotinic acid receptor 1 antagonist | 0.04 0.003 DBMET03565 | DBMET03565 | |
| 0.014 | 0.44 | 0.088 | Phospholipase D inhibitor | 0.088 0.024 DBMET03565 | DBMET03565 | |
| 0.022 | 0.452 | 0.092 | Chelator | 0.092 0.089 DBMET03565 | DBMET03565 | |
| 0.008 | 0.44 | 0.047 | Glutamate (mGluR1a) antagonist | 0.047 0.023 DBMET03565 | DBMET03565 | |
| 0.049 | 0.482 | 0.182 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.182 0.031 DBMET03565 | DBMET03565 | |
| 0.005 | 0.439 | 0.023 | Somatostatin 3 antagonist | 0.023 0.012 DBMET03565 | DBMET03565 | |
| 0.01 | 0.445 | 0.102 | Aconitate hydratase inhibitor | 0.049 0.041 DBMET03563 0.102 0.008 DBMET03565 | DBMET03565 | |
| 0.004 | 0.439 | 0.019 | Kainate receptor 3 antagonist | 0.019 0.009 DBMET03565 | DBMET03565 | |
| 0.005 | 0.444 | 0.084 | Prostaglandin E2 antagonist | 0.084 0.019 DBMET03565 | DBMET03565 | |
| 0.011 | 0.45 | 0.041 | AICAR transformylase inhibitor | 0.041 0.036 DBMET03565 | DBMET03565 | |
| 0.006 | 0.447 | 0.122 | GABA A receptor antagonist | 0.122 0.012 DBMET03565 | DBMET03565 | |
| 0.013 | 0.456 | 0.078 | Cyclin D1 inhibitor | 0.078 0.02 DBMET03565 | DBMET03565 | |
| 0.027 | 0.472 | 0.099 | Carbonic anhydrase III inhibitor | 0.099 0.063 DBMET03565 | DBMET03565 | |
| 0.002 | 0.45 | 0.066 | AMPA 1 receptor antagonist | 0.066 0.008 DBMET03565 | DBMET03565 | |
| 0.016 | 0.464 | 0.209 | Macrophage migration inhibitory factor inhibitor | 0.209 0.007 DBMET03565 | DBMET03565 | |
| 0.006 | 0.455 | 0.127 | Dihydroorotate dehydrogenase inhibitor | 0.127 0.006 DBMET03565 | DBMET03565 | |
| 0.005 | 0.455 | 0.057 | 5 Hydroxytryptamine 1 agonist | 0.057 0.034 DBMET03565 | DBMET03565 | |
| 0.014 | 0.464 | 0.067 | Glutamate (mGluR4) antagonist | 0.067 0.011 DBMET03565 | DBMET03565 | |
| 0.028 | 0.481 | 0.21 | DOPA decarboxylase inhibitor | 0.21 0.005 DBMET03565 | DBMET03565 | |
| 0.014 | 0.47 | 0.071 | Glutamate (mGluR7) antagonist | 0.071 0.041 DBMET03565 | DBMET03565 | |
| 0.051 | 0.508 | 0.221 | Superoxide dismutase inhibitor | 0.221 0.097 DBMET03565 | DBMET03565 | |
| 0.019 | 0.477 | 0.161 | 5 Hydroxytryptamine 3A agonist | 0.161 0.03 DBMET03565 | DBMET03565 | |
| 0.005 | 0.468 | 0.133 | GABA receptor antagonist | 0.133 0.011 DBMET03565 | DBMET03565 | |
| 0.038 | 0.501 | 0.217 | GABA C receptor rho-2 antagonist | 0.217 0.021 DBMET03565 | DBMET03565 | |
| 0.091 | 0.555 | 0.405 | Antiinflammatory | 0.405 0.136 DBMET03565 | DBMET03565 | |
| 0.028 | 0.496 | 0.154 | Aldehyde dehydrogenase inhibitor | 0.154 0.045 DBMET03565 | DBMET03565 | |
| 0.004 | 0.475 | 0.021 | Lysophosphatidic acid 1 receptor antagonist | 0.021 0.015 DBMET03565 | DBMET03565 | |
| 0.009 | 0.48 | 0.034 | Tryptophan 5 hydroxylase inhibitor | 0.034 0.029 DBMET03565 | DBMET03565 | |
| 0.084 | 0.556 | 0.149 | Heat shock protein 70 antagonist | 0.149 0.047 DBMET03565 | DBMET03565 | |
| 0.002 | 0.478 | 0.045 | Uridine phosphorylase inhibitor | 0.045 0.01 DBMET03565 | DBMET03565 | |
| 0.013 | 0.49 | 0.066 | Heparanase inhibitor | 0.066 0.015 DBMET03565 | DBMET03565 | |
| 0.009 | 0.49 | 0.096 | DNA gyrase inhibitor | 0.096 0.019 DBMET03565 | DBMET03565 | |
| 0.006 | 0.487 | 0.219 | Protein kinase (CK2) inhibitor | 0.219 0.015 DBMET03565 | DBMET03565 | |
| 0.03 | 0.512 | 0.124 | Interleukin 1 antagonist | 0.124 0.083 DBMET03565 | DBMET03565 | |
| 0.07 | 0.552 | 0.366 | Calcium channel activator | 0.366 0.04 DBMET03565 | DBMET03565 | |
| 0.031 | 0.514 | 0.308 | Peroxidase inhibitor | 0.308 0.036 DBMET03565 | DBMET03565 | |
| 0.013 | 0.496 | 0.072 | Glutamate (mGluR group III) antagonist | 0.072 0.009 DBMET03565 | DBMET03565 | |
| 0.004 | 0.491 | 0.028 | Protocollagen prolyl hydroxylase inhibitor | 0.028 0.019 DBMET03565 | DBMET03565 | |
| 0.003 | 0.49 | 0.102 | Cholecystokinin A antagonist | 0.102 0.008 DBMET03565 | DBMET03565 | |
| 0.003 | 0.491 | 0.078 | Kainate receptor 2 antagonist | 0.078 0.007 DBMET03565 | DBMET03565 | |
| 0.017 | 0.505 | 0.345 | Ferrochelatase inhibitor | 0.345 0.005 DBMET03565 | DBMET03565 | |
| 0.004 | 0.499 | 0.036 | DNA gyrase subunit B inhibitor | 0.036 0.03 DBMET03565 | DBMET03565 | |
| 0.003 | 0.502 | 0.055 | Farnesoid X receptor agonist | 0.055 0.012 DBMET03565 | DBMET03565 | |
| 0.004 | 0.504 | 0.08 | Glutamate (mGluR1) antagonist | 0.08 0.023 DBMET03565 | DBMET03565 | |
| 0.018 | 0.521 | 0.136 | Aminopeptidase B inhibitor | 0.136 0.044 DBMET03565 | DBMET03565 | |
| 0.049 | 0.558 | 0.376 | Antibacterial | 0.376 0.088 DBMET03565 | DBMET03565 | |
| 0.016 | 0.526 | 0.341 | GABA C receptor agonist | 0.341 0.007 DBMET03565 | DBMET03565 | |
| 0.019 | 0.53 | 0.075 | Carbonic anhydrase VI inhibitor | 0.075 0.064 DBMET03565 | DBMET03565 | |
| 0.014 | 0.526 | 0.095 | Histamine N-methyltransferase inhibitor | 0.095 0.051 DBMET03565 | DBMET03565 | |
| 0.008 | 0.521 | 0.14 | Glutamate decarboxylase inhibitor | 0.14 0.015 DBMET03565 | DBMET03565 | |
| 0.061 | 0.575 | 0.155 | Catenin beta inhibitor | 0.155 0.094 DBMET03565 | DBMET03565 | |
| 0.017 | 0.533 | 0.13 | GABA B receptor agonist | 0.13 0.005 DBMET03565 | DBMET03565 | |
| 0.03 | 0.55 | 0.116 | D-Ala-D-Ala ligase inhibitor | 0.116 0.016 DBMET03565 | DBMET03565 | |
| 0.004 | 0.525 | 0.042 | Sphingosine 1-phosphate receptor agonist | 0.042 0.034 DBMET03565 | DBMET03565 | |
| 0.024 | 0.545 | 0.085 | Granulocyte macrophage colony stimulating factor agonist | 0.085 0.061 DBMET03565 | DBMET03565 | |
| 0.019 | 0.54 | 0.082 | Potassium channel large-conductance Ca-activated activator | 0.082 0.034 DBMET03565 | DBMET03565 | |
| 0.02 | 0.544 | 0.106 | Cathepsin H inhibitor | 0.106 0.097 DBMET03565 | DBMET03565 | |
| 0.014 | 0.542 | 0.192 | GABA C receptor antagonist | 0.192 0.014 DBMET03565 | DBMET03565 | |
| 0.028 | 0.558 | 0.167 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.167 0.098 DBMET03565 | DBMET03565 | |
| 0.004 | 0.535 | 0.048 | NMDA 2A receptor antagonist | 0.048 0.04 DBMET03565 | DBMET03565 | |
| 0.01 | 0.541 | 0.066 | Aminopeptidase I inhibitor | 0.066 0.059 DBMET03565 | DBMET03565 | |
| 0.021 | 0.56 | 0.259 | Triose-phosphate isomerase inhibitor | 0.259 0.006 DBMET03565 | DBMET03565 | |
| 0.011 | 0.551 | 0.108 | Urease inhibitor | 0.108 0.057 DBMET03565 | DBMET03565 | |
| 0.005 | 0.545 | 0.109 | Alcohol oxidase inhibitor | 0.109 0.016 DBMET03565 | DBMET03565 | |
| 0.027 | 0.567 | 0.131 | MAP3K9 inhibitor | 0.131 0.093 DBMET03565 | DBMET03565 | |
| 0.025 | 0.566 | 0.22 | Antiamyloidogenic | 0.22 0.087 DBMET03565 | DBMET03565 | |
| 0.004 | 0.545 | 0.099 | Cholecystokinin antagonist | 0.099 0.008 DBMET03565 | DBMET03565 | |
| 0.015 | 0.556 | 0.211 | Potassium channel (Ca-activated) activator | 0.211 0.012 DBMET03565 | DBMET03565 | |
| 0.017 | 0.565 | 0.193 | GABA C receptor rho-1 antagonist | 0.193 0.009 DBMET03565 | DBMET03565 | |
| 0.012 | 0.561 | 0.048 | 5 Hydroxytryptamine 1B agonist | 0.048 0.046 DBMET03565 | DBMET03565 | |
| 0.026 | 0.576 | 0.14 | Photosensitizer | 0.14 0.038 DBMET03565 | DBMET03565 | |
| 0.037 | 0.589 | 0.194 | CF transmembrane conductance regulator agonist | 0.194 0.025 DBMET03565 | DBMET03565 | |
| 0.057 | 0.609 | 0.453 | GABA C receptor rho-3 antagonist | 0.453 0.041 DBMET03565 | DBMET03565 | |
| 0.005 | 0.561 | 0.119 | Biliverdin reductase inhibitor | 0.119 0.014 DBMET03565 | DBMET03565 | |
| 0.051 | 0.607 | 0.324 | Lipocortins synthesis antagonist | 0.324 0.017 DBMET03565 | DBMET03565 | |
| 0.021 | 0.581 | 0.159 | EphB2 antagonist | 0.159 0.12 DBMET03565 | DBMET03565 | |
| 0.016 | 0.58 | 0.081 | Glutamate dehydrogenase inhibitor | 0.081 0.043 DBMET03565 | DBMET03565 | |
| 0.013 | 0.584 | 0.157 | Creatine kinase inhibitor | 0.157 0.021 DBMET03565 | DBMET03565 | |
| 0.031 | 0.604 | 0.253 | Interleukin agonist | 0.253 0.077 DBMET03565 | DBMET03565 | |
| 0.009 | 0.581 | 0.05 | Glutamate (mGluR8) agonist | 0.05 0.011 DBMET03565 | DBMET03565 | |
| 0.005 | 0.579 | 0.112 | GABA B receptor antagonist | 0.112 0.005 DBMET03565 | DBMET03565 | |
| 0.003 | 0.578 | 0.054 | Nicotinic acid receptor 2 antagonist | 0.054 0.004 DBMET03565 | DBMET03565 | |
| 0.03 | 0.606 | 0.186 | Adenylate kinase inhibitor | 0.186 0.017 DBMET03565 | DBMET03565 | |
| 0.015 | 0.592 | 0.082 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.082 0.06 DBMET03565 | DBMET03565 | |
| 0.003 | 0.588 | 0.048 | Cholecystokinin B antagonist | 0.048 0.011 DBMET03565 | DBMET03565 | |
| 0.004 | 0.593 | 0.21 | Protein kinase (CK2) alpha inhibitor | 0.21 0.022 DBMET03565 | DBMET03565 | |
| 0.01 | 0.598 | 0.106 | Topoisomerase II inhibitor | 0.106 0.08 DBMET03565 | DBMET03565 | |
| 0.002 | 0.59 | 0.027 | NMDA receptor glycine site antagonist | 0.027 0.015 DBMET03565 | DBMET03565 | |
| 0.003 | 0.592 | 0.016 | Cholecystokinin A agonist | 0.016 0.011 DBMET03565 | DBMET03565 | |
| 0.004 | 0.593 | 0.066 | Prostaglandin EP2 antagonist | 0.066 0.036 DBMET03565 | DBMET03565 | |
| 0.02 | 0.611 | 0.174 | Cell wall synthesis inhibitor | 0.174 0.044 DBMET03565 | DBMET03565 | |
| 0.02 | 0.614 | 0.118 | NADH dehydrogenase inhibitor | 0.118 0.03 DBMET03565 | DBMET03565 | |
| 0.005 | 0.6 | 0.05 | Factor XIa inhibitor | 0.05 0.018 DBMET03565 | DBMET03565 | |
| 0.005 | 0.603 | 0.033 | NMDA 2D receptor antagonist | 0.033 0.013 DBMET03565 | DBMET03565 | |
| 0.014 | 0.613 | 0.186 | Beta glucuronidase inhibitor | 0.186 0.015 DBMET03565 | DBMET03565 | |
| 0.005 | 0.609 | 0.041 | AMPA 4 receptor antagonist | 0.041 0.024 DBMET03565 | DBMET03565 | |
| 0.014 | 0.62 | 0.183 | Keratolytic | 0.183 0.01 DBMET03565 | DBMET03565 | |
| 0.01 | 0.617 | 0.399 | Aryl hydrocarbon receptor agonist | 0.399 0.038 DBMET03565 | DBMET03565 | |
| 0.002 | 0.612 | 0.075 | Kainate receptor antagonist | 0.075 0.011 DBMET03565 | DBMET03565 | |
| 0.009 | 0.619 | 0.04 | Cholecystokinin B agonist | 0.04 0.024 DBMET03565 | DBMET03565 | |
| 0.042 | 0.657 | 0.347 | Vasodilator, peripheral | 0.347 0.075 DBMET03565 | DBMET03565 | |
| 0.013 | 0.631 | 0.172 | I kappa B kinase epsilon inhibitor | 0.172 0.097 DBMET03565 | DBMET03565 | |
| 0.004 | 0.624 | 0.054 | Glutamate (mGluR3) antagonist | 0.054 0.011 DBMET03565 | DBMET03565 | |
| 0.01 | 0.631 | 0.264 | Pyruvate kinase inhibitor | 0.264 0.057 DBMET03565 | DBMET03565 | |
| 0.005 | 0.627 | 0.184 | Catalase inhibitor | 0.184 0.018 DBMET03565 | DBMET03565 | |
| 0.01 | 0.634 | 0.046 | DNA gyrase subunit A inhibitor | 0.046 0.023 DBMET03565 | DBMET03565 | |
| 0.007 | 0.632 | 0.064 | NMDA receptor agonist | 0.064 0.042 DBMET03565 | DBMET03565 | |
| 0.011 | 0.639 | 0.24 | Anticonvulsant | 0.24 0.061 DBMET03565 | DBMET03565 | |
| 0.006 | 0.636 | 0.069 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.069 0.062 DBMET03565 | DBMET03565 | |
| 0.024 | 0.655 | 0.176 | ATPase inhibitor | 0.176 0.063 DBMET03565 | DBMET03565 | |
| 0.055 | 0.686 | 0.17 | Ca2+-transporting ATPase inhibitor | 0.17 0.013 DBMET03565 | DBMET03565 | |
| 0.003 | 0.635 | 0.016 | Cholecystokinin agonist | 0.016 0.015 DBMET03565 | DBMET03565 | |
| 0.003 | 0.637 | 0.067 | NMDA 2 receptor antagonist | 0.067 0.055 DBMET03565 | DBMET03565 | |
| 0.01 | 0.644 | 0.112 | Cystathionine beta-synthase inhibitor | 0.112 0.065 DBMET03565 | DBMET03565 | |
| 0.084 | 0.719 | 0.487 | Calcium channel L-type activator | 0.487 0.033 DBMET03565 | DBMET03565 | |
| 0.015 | 0.65 | 0.132 | Dual specificity phosphatase inhibitor | 0.132 0.117 DBMET03565 | DBMET03565 | |
| 0.004 | 0.644 | 0.064 | Phosphofructokinase-1 inhibitor | 0.064 0.053 DBMET03565 | DBMET03565 | |
| 0.017 | 0.658 | 0.074 | MAP kinase kinase 7 inhibitor | 0.074 0.065 DBMET03565 | DBMET03565 | |
| 0.021 | 0.663 | 0.124 | Adenylate cyclase stimulant | 0.124 0.115 DBMET03565 | DBMET03565 | |
| 0.005 | 0.647 | 0.037 | Somatostatin 1 antagonist | 0.037 0.028 DBMET03565 | DBMET03565 | |
| 0.005 | 0.651 | 0.075 | Diacylglycerol O-acyltransferase inhibitor | 0.075 0.017 DBMET03565 | DBMET03565 | |
| 0.003 | 0.651 | 0.039 | NMDA receptor subunit 3B antagonist | 0.039 0.037 DBMET03565 | DBMET03565 | |
| 0.024 | 0.672 | 0.211 | Antithrombotic | 0.211 0.164 DBMET03565 | DBMET03565 | |
| 0.016 | 0.667 | 0.163 | HIV-1 integrase (Overall Integration) inhibitor | 0.163 0.021 DBMET03565 | DBMET03565 | |
| 0.013 | 0.667 | 0.05 | CD45 antagonist | 0.05 0.036 DBMET03565 | DBMET03565 | |
| 0.003 | 0.658 | 0.068 | NMDA receptor glycine site agonist | 0.068 0.038 DBMET03565 | DBMET03565 | |
| 0.012 | 0.668 | 0.097 | Prolactin inhibitor | 0.097 0.059 DBMET03565 | DBMET03565 | |
| 0.012 | 0.674 | 0.254 | Alpha-N-acetylglucosaminidase inhibitor | 0.254 0.022 DBMET03565 | DBMET03565 | |
| 0.006 | 0.668 | 0.101 | Androgen antagonist | 0.101 0.046 DBMET03565 | DBMET03565 | |
| 0.005 | 0.674 | 0.044 | Plasminogen activator inhibitor antagonist | 0.044 0.041 DBMET03565 | DBMET03565 | |
| 0.014 | 0.684 | 0.107 | Adenylate cyclase inhibitor | 0.107 0.078 DBMET03565 | DBMET03565 | |
| 0.007 | 0.678 | 0.141 | Anesthetic general | 0.141 0.124 DBMET03565 | DBMET03565 | |
| 0.01 | 0.683 | 0.15 | UDP-glucose 4-epimerase inhibitor | 0.15 0.029 DBMET03565 | DBMET03565 | |
| 0.016 | 0.69 | 0.21 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.21 0.014 DBMET03565 | DBMET03565 | |
| 0.003 | 0.679 | 0.053 | Phosphorylase inhibitor | 0.053 0.028 DBMET03565 | DBMET03565 | |
| 0.051 | 0.73 | 0.22 | Tyrosine 3 hydroxylase inhibitor | 0.22 0.103 DBMET03565 | DBMET03565 | |
| 0.003 | 0.683 | 0.029 | Kainate receptor 4 antagonist | 0.029 0.014 DBMET03565 | DBMET03565 | |
| 0.028 | 0.708 | 0.297 | Gastrin inhibitor | 0.297 0.035 DBMET03565 | DBMET03565 | |
| 0.016 | 0.698 | 0.217 | Hemostatic | 0.217 0.027 DBMET03565 | DBMET03565 | |
| 0.004 | 0.687 | 0.1 | Xanthine dehydrogenase inhibitor | 0.1 0.016 DBMET03565 | DBMET03565 | |
| 0.003 | 0.686 | 0.077 | Argininosuccinate synthase inhibitor | 0.077 0.027 DBMET03565 | DBMET03565 | |
| 0.01 | 0.694 | 0.056 | Dihydroorotate oxidase inhibitor | 0.056 0.035 DBMET03565 | DBMET03565 | |
| 0.007 | 0.692 | 0.039 | Kainate receptor agonist | 0.039 0.036 DBMET03565 | DBMET03565 | |
| 0.029 | 0.715 | 0.194 | Vasodilator, coronary | 0.194 0.188 DBMET03565 | DBMET03565 | |
| 0.014 | 0.701 | 0.315 | DNA synthesis inhibitor | 0.315 0.039 DBMET03565 | DBMET03565 | |
| 0.011 | 0.699 | 0.055 | Purinergic P2X1 antagonist | 0.055 0.052 DBMET03565 | DBMET03565 | |
| 0.018 | 0.706 | 0.167 | Sphingosine 1-phosphate receptor 5 antagonist | 0.167 0.037 DBMET03565 | DBMET03565 | |
| 0.004 | 0.692 | 0.037 | Leukotriene C4 antagonist | 0.037 0.032 DBMET03565 | DBMET03565 | |
| 0.003 | 0.693 | 0.028 | Kainate receptor 5 antagonist | 0.028 0.01 DBMET03565 | DBMET03565 | |
| 0.007 | 0.699 | 0.099 | Glycine receptor antagonist | 0.099 0.033 DBMET03565 | DBMET03565 | |
| 0.004 | 0.697 | 0.107 | NMDA receptor antagonist | 0.107 0.043 DBMET03565 | DBMET03565 | |
| 0.009 | 0.705 | 0.137 | Uric acid excretion stimulant | 0.137 0.029 DBMET03565 | DBMET03565 | |
| 0.01 | 0.71 | 0.08 | Histone deacetylase stimulant | 0.08 0.044 DBMET03565 | DBMET03565 | |
| 0.01 | 0.71 | 0.08 | Histone deacetylase SIRT1 stimulant | 0.08 0.044 DBMET03565 | DBMET03565 | |
| 0.012 | 0.713 | 0.166 | Xanthine oxidase inhibitor | 0.166 0.029 DBMET03565 | DBMET03565 | |
| 0.038 | 0.742 | 0.247 | Apoptosis antagonist | 0.247 0.13 DBMET03565 | DBMET03565 | |
| 0.004 | 0.71 | 0.058 | Leukotriene C antagonist | 0.058 0.035 DBMET03565 | DBMET03565 | |
| 0.005 | 0.711 | 0.155 | Glutamate receptor antagonist | 0.155 0.048 DBMET03565 | DBMET03565 | |
| 0.02 | 0.73 | 0.164 | Neurotensin receptor agonist | 0.164 0.072 DBMET03565 | DBMET03565 | |
| 0.014 | 0.728 | 0.158 | Insulin secretagoues | 0.158 0.066 DBMET03565 | DBMET03565 | |
| 0.002 | 0.717 | 0.034 | Retinoid X alpha receptor agonist | 0.034 0.025 DBMET03565 | DBMET03565 | |
| 0.041 | 0.756 | 0.32 | Caspase 9 stimulant | 0.32 0.173 DBMET03565 | DBMET03565 | |
| 0.021 | 0.738 | 0.167 | Interferon gamma antagonist | 0.167 0.059 DBMET03565 | DBMET03565 | |
| 0.01 | 0.727 | 0.153 | Toll-Like receptor 2 antagonist | 0.153 0.05 DBMET03565 | DBMET03565 | |
| 0.012 | 0.729 | 0.083 | Glutamate (mGluR6) antagonist | 0.083 0.021 DBMET03565 | DBMET03565 | |
| 0.015 | 0.732 | 0.2 | Aldehyde oxidase inhibitor | 0.2 0.105 DBMET03565 | DBMET03565 | |
| 0.028 | 0.746 | 0.458 | Histamine release inhibitor | 0.458 0.046 DBMET03565 | DBMET03565 | |
| 0.008 | 0.728 | 0.086 | Ornithine decarboxylase inhibitor | 0.086 0.06 DBMET03565 | DBMET03565 | |
| 0.001 | 0.721 | 0.046 | Kainate receptor 1 antagonist | 0.046 0.006 DBMET03565 | DBMET03565 | |
| 0.013 | 0.734 | 0.19 | Succinate dehydrogenase inhibitor | 0.19 0.058 DBMET03565 | DBMET03565 | |
| 0.004 | 0.726 | 0.094 | Histidine decarboxylase inhibitor | 0.094 0.034 DBMET03565 | DBMET03565 | |
| 0.02 | 0.743 | 0.306 | Cholesterol antagonist | 0.306 0.087 DBMET03565 | DBMET03565 | |
| 0.003 | 0.729 | 0.129 | Nicotinic acid receptor agonist | 0.129 0.004 DBMET03565 | DBMET03565 | |
| 0.001 | 0.73 | 0.031 | Retinoid X receptor agonist | 0.031 0.029 DBMET03565 | DBMET03565 | |
| 0.012 | 0.745 | 0.259 | Interleukin antagonist | 0.259 0.058 DBMET03565 | DBMET03565 | |
| 0.002 | 0.749 | 0.057 | NMDA 2C receptor antagonist | 0.057 0.05 DBMET03565 | DBMET03565 | |
| 0.003 | 0.753 | 0.095 | Monophenol monooxygenase inhibitor | 0.095 0.08 DBMET03565 | DBMET03565 | |
| 0.022 | 0.772 | 0.215 | RNA-directed DNA polymerase inhibitor | 0.215 0.079 DBMET03565 | DBMET03565 | |
| 0.004 | 0.756 | 0.153 | Psychostimulant | 0.153 0.113 DBMET03565 | DBMET03565 | |
| 0.005 | 0.759 | 0.074 | GABA aminotransferase inhibitor | 0.074 0.055 DBMET03565 | DBMET03565 | |
| 0.022 | 0.782 | 0.244 | Hypoglycemic | 0.244 0.08 DBMET03565 | DBMET03565 | |
| 0.007 | 0.769 | 0.158 | Insulin sensitizer | 0.158 0.122 DBMET03565 | DBMET03565 | |
| 0.01 | 0.776 | 0.165 | DNA methyltransferase I inhibitor | 0.165 0.09 DBMET03565 | DBMET03565 | |
| 0.005 | 0.777 | 0.072 | CDC25B inhibitor | 0.072 0.036 DBMET03565 | DBMET03565 | |
| 0.014 | 0.791 | 0.102 | Nav1.4 sodium channel blocker | 0.102 0.073 DBMET03565 | DBMET03565 | |
| 0.006 | 0.79 | 0.089 | Falcipain 3 inhibitor | 0.089 0.082 DBMET03565 | DBMET03565 | |
| 0.001 | 0.786 | 0.014 | Retinoic acid beta receptor antagonist | 0.014 0.006 DBMET03565 | DBMET03565 | |
| 0.004 | 0.798 | 0.102 | Nicotinic acid receptor 2 agonist | 0.032 0.031 DBMET03563 0.102 0.005 DBMET03565 | DBMET03565 | |
| 0.011 | 0.808 | 0.157 | DNA methylase inhibitor | 0.157 0.111 DBMET03565 | DBMET03565 | |
| 0.014 | 0.823 | 0.065 | Adenine nucleotide translocase inhibitor | 0.065 0.02 DBMET03565 | DBMET03565 | |
| 0.003 | 0.821 | 0.03 | Retinoid X gamma receptor antagonist | 0.03 0.012 DBMET03565 | DBMET03565 | |
| 0.005 | 0.827 | 0.144 | Protein-tyrosine phosphatase inhibitor | 0.144 0.085 DBMET03565 | DBMET03565 | |
| 0.021 | 0.849 | 0.505 | 5 Hydroxytryptamine release inhibitor | 0.505 0.031 DBMET03565 | DBMET03565 | |
| 0.006 | 0.854 | 0.042 | Nicotinic acid receptor 1 agonist | 0.042 0.026 DBMET03565 | DBMET03565 | |
| 0.002 | 0.878 | 0.022 | Retinoic acid receptor antagonist | 0.022 0.009 DBMET03565 | DBMET03565 | |
| 0.002 | 0.882 | 0.033 | Retinoid X gamma receptor agonist | 0.033 0.009 DBMET03565 | DBMET03565 | |
| 0.001 | 0.884 | 0.012 | Retinoic acid receptor gamma antagonist | 0.012 0.008 DBMET03565 | DBMET03565 | |
| 0.036 | 0.924 | 0.202 | Interleukin 2 agonist | 0.202 0.186 DBMET03565 | DBMET03565 | |
| 0.004 | 0.898 | 0.091 | Protein-tyrosine phosphatase 1B inhibitor | 0.091 0.088 DBMET03565 | DBMET03565 | |
| 0.001 | 0.907 | 0.023 | Retinoid X beta receptor agonist | 0.023 0.013 DBMET03565 | DBMET03565 | |
| 0.001 | 0.936 | 0.024 | Retinoic acid alpha receptor antagonist | 0.024 0.01 DBMET03565 | DBMET03565 | |
| 0.007 | 0.944 | 0.038 | Glutamate (mGluR8) antagonist | 0.038 0.02 DBMET03565 | DBMET03565 | |
| 0.002 | 0.961 | 0.023 | Retinoic acid beta receptor agonist | 0.023 0.009 DBMET03565 | DBMET03565 | |
| 0.003 | 0.97 | 0.061 | Retinoic acid alpha receptor agonist | 0.061 0.009 DBMET03565 | DBMET03565 | |
| 0.002 | 0.974 | 0.03 | Retinoic acid receptor agonist | 0.03 0.01 DBMET03565 | DBMET03565 | |
| 0.002 | 0.981 | 0.024 | Retinoic acid gamma receptor agonist | 0.024 0.012 DBMET03565 | DBMET03565 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |